Person:
AÇIKGÖZ, NUSRET

Profile Picture
Google ScholarScopusORCIDPublons
Status
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
NUSRET
Last Name
AÇIKGÖZ
Name
Email Address
Birth Date

Filters

2022 - 20242
Reset filters

Settings

Subject: Eczacılık × Has files: false × Rights: info:eu-repo/semantics/openAccess ×

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    PublicationMetadata only
    Identification and evaluation of drug-related problems in the cardiology ward: an interventional study
    (2022-11-25) Sosyal D.; Bektay M. Y.; Açıkgöz N.; İzzettin F. V.; SOSYAL, DAMLA; BEKTAY, MUHAMMED YUNUS; AÇIKGÖZ, NUSRET; İZZETTİN, FIKRET VEHBI
  • No Thumbnail Available
    PublicationMetadata only
    Thymoquinone ameliorates symptoms of Parkinson's disease in a 6-OHDA rat model by downregulation of miR-204-3p
    (2024-06-01) Pala M.; Meral I.; AÇIKGÖZ N.; Mengi M.; Erdim Gokce M. B.; Unsal R.; Polat Y.; AKBAŞ F.; Gorucu Yilmaz S.; AÇIKGÖZ, NUSRET; AKBAŞ, FAHRİ
    microRNAs (miRNAs) play a significant role in the pathophysiology of Parkinson\"s disease. In this study, we evaluated the neuroprotective effect of thymoquinone on the expression profiles of miRNA and cognitive functions in the 6-hydroxydopamine (6-OHDA)-induced Parkinson\"s model. Male adult Wistar albino rats (200-230 g, n = 36) were randomly assigned to six groups: Sham, thymoquinone (10 mg/kg, p.o.), 6-OHDA, 6-OHDA + thymoquinone (10 mg/kg), 6-OHDA + thymoquinone (20 mg/kg), and 6-OHDA + thymoquinone (50 mg/kg). Behavioral changes were detected using the open field and the elevated plus maze tests. The mature 728 miRNA expressions were evaluated by miRNA microarray (GeneChip miRNA 4.0). Ten miRNAs were selected (rno-miR-212-5p, rno-miR-146b-5p, rno-miR-150-5p, rno-miR-29b-2-5p, rno-miR-126a-3p, rno-miR-187-3p, rno-miR-34a-5p, rno-miR-181d-5p, rno-miR-204-3p, and rno-miR-30c-2-3p) and confirmed by real-time PCR. Striatum samples were stained with hematoxylin-eosin to determine the effect of dopaminergic lesions. One-way ANOVA test and independent sample t -test were used for statistical analyses. rno-miR-204-3p was upregulated at 6-OHDA and downregulated at the 50 mg/kg dose of thymoquinone. In conclusion, thymoquinone at a dose of 50 mg/kg ameliorates symptoms of Parkinson\"s disease in a 6-OHDA rat model by downregulation of miR-204-3p. Also, the results showed that thymoquinone can improve locomotor activity and willing exploration and decreased anxiety. Therefore, thymoquinone can be used as a therapeutic agent.